Recombinant Cedar Virus: A Henipavirus Reverse Genetics Platform.

Cedar virus Henipavirus Reverse genetics Virus plaque assay Virus rescue Virus titration

Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2023
Historique:
medline: 24 8 2023
pubmed: 23 8 2023
entrez: 23 8 2023
Statut: ppublish

Résumé

The isolation of Cedar virus, a nonpathogenic henipavirus that is closely related to the highly pathogenic Nipah virus and Hendra virus, provides a new platform for henipavirus experimentation and a tool to investigate biological differences among these viruses under less stringent biological containment. Here, we detail a reverse genetics system used to rescue two replication-competent, recombinant Cedar virus variants: a recombinant wild-type Cedar virus and a recombinant Cedar virus that express a green fluorescent protein from an open reading frame inserted between the phosphoprotein and matrix genes. This recombinant Cedar virus platform may be utilized to characterize the determinants of pathogenesis across the henipaviruses, investigate their receptor tropisms, and identify novel pan-henipavirus antivirals safely under biosafety level-2 conditions.

Identifiants

pubmed: 37610574
doi: 10.1007/978-1-0716-3283-3_5
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

73-86

Subventions

Organisme : NIAID NIH HHS
ID : U19 AI142764
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI077995
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI054715
Pays : United States

Informations de copyright

© 2023. Springer Science+Business Media, LLC, part of Springer Nature.

Références

Luby SP (2013) The pandemic potential of Nipah virus. Antivir Res 100(1):38–43. https://doi.org/10.1016/j.antiviral.2013.07.011
doi: 10.1016/j.antiviral.2013.07.011 pubmed: 23911335
Luby SP, Broder CC (2014) Paramyxoviruses: henipaviruses. In: Kaslow RA, Stanberry LR, Le Duc JW (eds) Viral infections of humans, epidemiology and control. Springer, New York, pp 519–536
doi: 10.1007/978-1-4899-7448-8_22
Wang L-F, Mackenzie JS, Broder CC (2013) Henipaviruses. In: Knipe DM, Howley PM (eds) Fields virology, vol 1. Lippincott Williams & Wilkins, Philadelphia, pp 1070–1085
Broder CC, Weir DL, Reid PA (2016) Hendra virus and Nipah virus animal vaccines. Vaccine 34(30):3525–3534. https://doi.org/10.1016/j.vaccine.2016.03.075
doi: 10.1016/j.vaccine.2016.03.075 pubmed: 27154393 pmcid: 4933500
Broder CC, Wong KT (2016) Henipaviruses. In: Reiss CS (ed) Neurotropic viral infections, 2nd edn, vol 1. Springer, Cham, pp 45–83
doi: 10.1007/978-3-319-33133-1_3
Geisbert TW, Feldmann H, Broder CC (2012) Animal challenge models of Henipavirus infection and pathogenesis. Curr Top Microbiol Immunol 359:153–177. https://doi.org/10.1007/82_2012_208
doi: 10.1007/82_2012_208 pubmed: 22476556 pmcid: 7120132
Arunkumar G, Chandni R, Mourya DT, Singh SK, Sadanandan R, Sudan P, Bhargava B, Nipah Investigators P, Health Study G (2019) Outbreak investigation of Nipah virus disease in Kerala, India, 2018. J Infect Dis 219(12):1867–1878. https://doi.org/10.1093/infdis/jiy612
doi: 10.1093/infdis/jiy612 pubmed: 30364984
Broder CC, Xu K, Nikolov DB, Zhu Z, Dimitrov DS, Middleton D, Pallister J, Geisbert TW, Bossart KN, Wang LF (2013) A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antivir Res 100(1):8–13. https://doi.org/10.1016/j.antiviral.2013.06.012
doi: 10.1016/j.antiviral.2013.06.012 pubmed: 23838047
Amaya M, Broder CC (2020) Vaccines to emerging viruses: Nipah and Hendra. Annu Rev Virol 7(1):447–473. https://doi.org/10.1146/annurev-virology-021920-113833
doi: 10.1146/annurev-virology-021920-113833 pubmed: 32991264 pmcid: 8782152
Marsh GA, de Jong C, Barr JA, Tachedjian M, Smith C, Middleton D, Yu M, Todd S, Foord AJ, Haring V, Payne J, Robinson R, Broz I, Crameri G, Field HE, Wang LF (2012) Cedar virus: a novel Henipavirus isolated from Australian bats. PLoS Pathog 8(8):e1002836. https://doi.org/10.1371/journal.ppat.1002836
doi: 10.1371/journal.ppat.1002836 pubmed: 22879820 pmcid: 3410871
Schountz T, Campbell C, Wagner K, Rovnak J, Martellaro C, DeBuysscher BL, Feldmann H, Prescott J (2019) Differential innate immune responses elicited by Nipah virus and cedar virus correlate with disparate in vivo pathogenesis in hamsters. Viruses 11(3). https://doi.org/10.3390/v11030291
Beaty SM, Park A, Won ST, Hong P, Lyons M, Vigant F, Freiberg AN, tenOever BR, Duprex WP, Lee B (2017) Efficient and robust paramyxoviridae reverse genetics systems. mSphere 2(2). https://doi.org/10.1128/mSphere.00376-16
Conzelmann KK (2004) Reverse genetics of mononegavirales. Curr Top Microbiol Immunol 283:1–41. https://doi.org/10.1007/978-3-662-06099-5_1
doi: 10.1007/978-3-662-06099-5_1 pubmed: 15298166
Pfaller CK, Cattaneo R, Schnell MJ (2015) Reverse genetics of Mononegavirales: how they work, new vaccines, and new cancer therapeutics. Virology 479-480:331–344. https://doi.org/10.1016/j.virol.2015.01.029
doi: 10.1016/j.virol.2015.01.029 pubmed: 25702088
Schmidt KM, Muhlberger E (2016) Marburg virus reverse genetics systems. Viruses 8(6). https://doi.org/10.3390/v8060178
Ciancanelli MJ, Volchkova VA, Shaw ML, Volchkov VE, Basler CF (2009) Nipah virus sequesters inactive STAT1 in the nucleus via a P gene-encoded mechanism. J Virol 83(16):7828–7841. https://doi.org/10.1128/JVI.02610-08
doi: 10.1128/JVI.02610-08 pubmed: 19515782 pmcid: 2715789
Laing ED, Amaya M, Navaratnarajah CK, Feng YR, Cattaneo R, Wang LF, Broder CC (2018) Rescue and characterization of recombinant cedar virus, a non-pathogenic Henipavirus species. Virol J 15(1):56. https://doi.org/10.1186/s12985-018-0964-0
doi: 10.1186/s12985-018-0964-0 pubmed: 29587789 pmcid: 5869790
Lo MK, Peeples ME, Bellini WJ, Nichol ST, Rota PA, Spiropoulou CF (2012) Distinct and overlapping roles of Nipah virus P gene products in modulating the human endothelial cell antiviral response. PLoS One 7(10):e47790. https://doi.org/10.1371/journal.pone.0047790
doi: 10.1371/journal.pone.0047790 pubmed: 23094089 pmcid: 3477106
Marsh GA, Virtue ER, Smith I, Todd S, Arkinstall R, Frazer L, Monaghan P, Smith GA, Broder CC, Middleton D, Wang LF (2013) Recombinant Hendra viruses expressing a reporter gene retain pathogenicity in ferrets. Virol J 10:95. https://doi.org/10.1186/1743-422X-10-95
doi: 10.1186/1743-422X-10-95 pubmed: 23521919 pmcid: 3724489
Yoneda M, Guillaume V, Ikeda F, Sakuma Y, Sato H, Wild TF, Kai C (2006) Establishment of a Nipah virus rescue system. Proc Natl Acad Sci U S A 103(44):16508–16513. https://doi.org/10.1073/pnas.0606972103
doi: 10.1073/pnas.0606972103 pubmed: 17053073 pmcid: 1618306
Yun T, Park A, Hill TE, Pernet O, Beaty SM, Juelich TL, Smith JK, Zhang L, Wang YE, Vigant F, Gao J, Wu P, Lee B, Freiberg AN (2015) Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection. J Virol 89(2):1242–1253. https://doi.org/10.1128/JVI.02583-14
doi: 10.1128/JVI.02583-14 pubmed: 25392218
Satterfield BA, Cross RW, Fenton KA, Agans KN, Basler CF, Geisbert TW, Mire CE (2015) The immunomodulating V and W proteins of Nipah virus determine disease course. Nat Commun 6:7483. https://doi.org/10.1038/ncomms8483
doi: 10.1038/ncomms8483 pubmed: 26105519
Laing ED, Navaratnarajah CK, Cheliout Da Silva S, Petzing SR, Xu Y, Sterling SL, Marsh GA, Wang LF, Amaya M, Nikolov DB, Cattaneo R, Broder CC, Xu K (2019) Structural and functional analyses reveal promiscuous and species specific use of ephrin receptors by cedar virus. Proc Natl Acad Sci U S A 116(41):20707–20715. https://doi.org/10.1073/pnas.1911773116
doi: 10.1073/pnas.1911773116 pubmed: 31548390 pmcid: 6789926
Halpin K, Bankamp B, Harcourt BH, Bellini WJ, Rota PA (2004) Nipah virus conforms to the rule of six in a minigenome replication assay. J Gen Virol 85(Pt 3):701–707. https://doi.org/10.1099/vir.0.19685-0
doi: 10.1099/vir.0.19685-0 pubmed: 14993656
Buchholz UJ, Finke S, Conzelmann KK (1999) Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73(1):251–259
doi: 10.1128/JVI.73.1.251-259.1999 pubmed: 9847328 pmcid: 103829
Peeters BP, de Leeuw OS, Koch G, Gielkens AL (1999) Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 73(6):5001–5009
doi: 10.1128/JVI.73.6.5001-5009.1999 pubmed: 10233962 pmcid: 112544
Chan YP, Yan L, Feng YR, Broder CC (2009) Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery. Methods Mol biol 525:31-58, xiii. https://doi.org/10.1007/978-1-59745-554-1_2

Auteurs

Moushimi Amaya (M)

Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.

Christopher C Broder (CC)

Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.

Eric D Laing (ED)

Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA. eric.laing@usuhs.edu.

Articles similaires

Animals Swine Antiviral Agents Swine Diseases Coronavirus Infections
Humans Carcinoma, Hepatocellular Liver Neoplasms Aged United States
Drug Repositioning Humans SARS-CoV-2 COVID-19 Drug Treatment Antiviral Agents

Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients.

Fatemeh Saheb Sharif-Askari, Hawra Ali Hussain Alsayed, Narjes Saheb Sharif-Askari et al.
1.00
Ritonavir Humans Female Male Middle Aged

Classifications MeSH